Table 2. Paclitaxel-derived toxicities in the two study arms.
| Arm A (paclitaxel plus nintedanib) | Arm B (paclitaxel) | P value | |
|---|---|---|---|
| Grade 1 or 2 | |||
| Neuropathy (average, range) | 0.6 (0–3) | 1.1 (0–4) | 0.023 |
| Myalgia (average, range) | 0.3 (0–3) | 0.35 (0–3) | 0.689 |
| Fatigue (average, range) | 1.4 (0–4) | 1.6 (0–4) | 0.38 |
| Arm A (paclitaxel plus nintedanib) | Arm B (paclitaxel) | P value | |
| Grade 3 or 4 | |||
| Neuropathy (average, range) | 0 (0–0) | 0 (0–0) | N/A |
| Myalgia (average, range) | 0 (0–0) | 0 (0–0) | N/A |
| Fatigue (average, range) | 0 (0–0) | 0 (0–0) | N/A |